The Immunoscore, a quantitative measure of CD3+ and CD8+ T cell infiltration in tumor regions, has been validated as a robust prognostic biomarker (Zhao et al., 2019; Orhan et al., 2022). The gene discussed is CD8A; the disease is neoplasm.